University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

Active, not recruiting

Conditions: Hepatitis B

First Posted Date: 2013-02-21

Last Posted Date: 2025-01-14

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 40

Registration Number: NCT01796457

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 5 locations

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

Phase 1

Completed

Conditions: HIV

Interventions: Genetic: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.

First Posted Date: 2013-02-11

Last Posted Date: 2019-08-30

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 10

Registration Number: NCT01787994

Locations: 🇺🇸
Division of Infectious Diseases & HIV Medicine at Drexel University College of Medicine, Philadelphia, Pennsylvania, United States

Nicotine Receptor Levels and Smoking Cessation

Completed

Conditions: Nicotine Addiction
Smoking Cessation

First Posted Date: 2013-02-11

Last Posted Date: 2018-03-12

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 24

Registration Number: NCT01788943

Locations: 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Mendelian Reverse Cholesterol Transport Study

Not Applicable

Suspended

Conditions: Cholesterol, HDL
Tangier Disease
Lipid Metabolism, Inborn Errors
Cholesteryl Ester Transfer Protein (CETP) Deficiency
LCAT Deficiency

Interventions: Drug: 3H-cholesterol bound to albumin

First Posted Date: 2013-02-01

Last Posted Date: 2024-05-16

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 30

Registration Number: NCT01782027

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Communicating Smoking Risks Through Graphic Warning Labels

Phase 3

Completed

Conditions: Lung Cancer
Heart Disease

Interventions: Behavioral: Control
Behavioral: Picture warning

First Posted Date: 2013-02-01

Last Posted Date: 2014-12-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 245

Registration Number: NCT01782053

Locations: 🇺🇸
Annenberg Public Policy Center, Philadelphia, Pennsylvania, United States
🇺🇸
Lazenby Hall, Ohio State University, Columbus, Ohio, United States

Remote Observed Dosing to Increase Suboxone Compliance

Not Applicable

Completed

Conditions: Opiate Dependence

Interventions: Behavioral: Remote Observed Dosing

First Posted Date: 2013-01-30

Last Posted Date: 2017-11-07

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 9

Registration Number: NCT01779973

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)

Early Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: EC17

First Posted Date: 2013-01-29

Last Posted Date: 2018-07-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 10

Registration Number: NCT01778933

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

Phase 1

Completed

Conditions: Nodules
Lung and Pleural Malignancies
Neoplasms
Adenocarcinoma

Interventions: Drug: EC17 imaging contrast agent

First Posted Date: 2013-01-29

Last Posted Date: 2016-05-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 48

Registration Number: NCT01778920

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Philadelphia VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States

Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

Phase 2

Terminated

Conditions: HIV
Heavy Drinking
Alcohol Dependence

Interventions: Drug: Topiramate
Drug: Placebo
Behavioral: Medical Management

First Posted Date: 2013-01-09

Last Posted Date: 2016-03-15

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 4

Registration Number: NCT01764685

Locations: 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States

Extended Varenicline Treatment for Smoking Among Cancer Patients

Phase 3

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Varenicline
Drug: Placebo
Behavioral: Smoking Cessation Counseling

First Posted Date: 2012-12-28

Last Posted Date: 2019-07-30

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 207

Registration Number: NCT01756885

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy